Matteo Zignol

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. pmc Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010
    Matteo Zignol
    Stop TB Department, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
    Bull World Health Organ 90:111-119D. 2012
  2. pmc Implementation of a national anti-tuberculosis drug resistance survey in Tanzania
    Timothy M Chonde
    1National Tuberculosis and Leprosy Control Program, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
    BMC Public Health 8:427. 2008
  3. pmc Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 52:901-6. 2011
  4. ncbi request reprint Global incidence of multidrug-resistant tuberculosis
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva 1211, Switzerland
    J Infect Dis 194:479-85. 2006
  5. ncbi request reprint Patients with previously treated tuberculosis no longer neglected
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva, CH 1211, Switzerland
    Clin Infect Dis 44:61-4. 2007
  6. doi request reprint Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance
    Abigail Wright
    Stop TB Department, WHO, Geneva, Switzerland
    Lancet 373:1861-73. 2009
  7. pmc Multidrug-resistant tuberculosis in children: evidence from global surveillance
    Matteo Zignol
    World Health Organization, Geneva, Switzerland
    Eur Respir J 42:701-7. 2013
  8. doi request reprint Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data
    Dennis Falzon
    Stop TB Department, World Health Organization, Geneva, Switzerland Electronic address
    Lancet Infect Dis 13:690-7. 2013
  9. ncbi request reprint Tb drug resistance: is it really a threat to Africa?
    Paul Nunn
    World Health Organization, Stop TB Department, Avenue Appia 1211 Geneva, Switzerland
    Ethiop Med J 45:399-404. 2007
  10. doi request reprint Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
    Karin Weyer
    Stop TB Dept, World Health Organization, Geneva, Switzerland
    Eur Respir J 42:252-71. 2013

Collaborators

Detail Information

Publications15

  1. pmc Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010
    Matteo Zignol
    Stop TB Department, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
    Bull World Health Organ 90:111-119D. 2012
    ..To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994-2010...
  2. pmc Implementation of a national anti-tuberculosis drug resistance survey in Tanzania
    Timothy M Chonde
    1National Tuberculosis and Leprosy Control Program, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
    BMC Public Health 8:427. 2008
    ..The current manuscript describes the implementation of the first national drug resistance survey in Tanzania...
  3. pmc Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 52:901-6. 2011
    ..Routine surveillance linked to patient care, which represents the best approach to monitor drug resistance, now has the possibility of becoming a reality even in resource-limited countries...
  4. ncbi request reprint Global incidence of multidrug-resistant tuberculosis
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva 1211, Switzerland
    J Infect Dis 194:479-85. 2006
    ....
  5. ncbi request reprint Patients with previously treated tuberculosis no longer neglected
    Matteo Zignol
    Stop TB Department, World Health Organization, Geneva, CH 1211, Switzerland
    Clin Infect Dis 44:61-4. 2007
    ..Previously treated patients are difficult to re-treat and represent an important source of disease transmission, as well as a serious threat to TB control worldwide, because of their higher rate of drug resistance...
  6. doi request reprint Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance
    Abigail Wright
    Stop TB Department, WHO, Geneva, Switzerland
    Lancet 373:1861-73. 2009
    ..The Global Project on Anti-Tuberculosis Drug Resistance has been gathering data since 1994. This study provides the latest data on the extent of drug resistance worldwide...
  7. pmc Multidrug-resistant tuberculosis in children: evidence from global surveillance
    Matteo Zignol
    World Health Organization, Geneva, Switzerland
    Eur Respir J 42:701-7. 2013
    ..Of particular concern is the association found between age <15 years and MDR-TB in southern African countries with high HIV prevalence. ..
  8. doi request reprint Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data
    Dennis Falzon
    Stop TB Department, World Health Organization, Geneva, Switzerland Electronic address
    Lancet Infect Dis 13:690-7. 2013
    ..We assessed the progress towards the 2015 targets achieved by countries accounting for 90% of the estimated MDR-tuberculosis cases in the world in 2011...
  9. ncbi request reprint Tb drug resistance: is it really a threat to Africa?
    Paul Nunn
    World Health Organization, Stop TB Department, Avenue Appia 1211 Geneva, Switzerland
    Ethiop Med J 45:399-404. 2007
    ..This paper analyses the threat of TB drug resistance to health and to TB control in Africa, and puts forward measures to diminish this threat...
  10. doi request reprint Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
    Karin Weyer
    Stop TB Dept, World Health Organization, Geneva, Switzerland
    Eur Respir J 42:252-71. 2013
    ....
  11. pmc Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India
    Katherine Floyd
    HIV AIDS, TB and Malaria, World Health Organization, 1211 Geneva 27, Switzerland
    Bull World Health Organ 84:437-45. 2006
    ..To assess the cost and cost-effectiveness of the Public-Private Mix DOTS (PPM-DOTS) strategy for tuberculosis (TB) control in India...
  12. pmc Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda
    Frank G J Cobelens
    KNCV Tuberculosis Foundation, The Hague, The Netherlands
    PLoS Med 5:e150. 2008
  13. pmc Challenges in estimating the total burden of drug-resistant tuberculosis
    Ted Cohen
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Respir Crit Care Med 177:1302-6. 2008
    ....
  14. pmc Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study
    Ted Cohen
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 3:e2363. 2008
    ....
  15. pmc A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis
    Gyanu Lamichhane
    Center for Tuberculosis Research, Department of Medicine, The Johns Hopkins University School of Medicine, 424 North Bond Street, Baltimore, MD 21231 1001, USA
    Proc Natl Acad Sci U S A 100:7213-8. 2003
    ..At subsaturation levels of mutagenesis with a random transposon such as Himar1, this approach permits a statistical prediction of both the proportion and identities of essential genes of sequenced genomes...